Heron Therapeutics (HRTX) Competitors $1.35 -0.04 (-2.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.38 +0.02 (+1.85%) As of 08/29/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. PHAT, AVXL, AKBA, VALN, NAGE, SANA, TSHA, GYRE, AVBP, and BGMShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Phathom Pharmaceuticals (PHAT), Anavex Life Sciences (AVXL), Akebia Therapeutics (AKBA), Valneva (VALN), Niagen Bioscience (NAGE), Sana Biotechnology (SANA), Taysha Gene Therapies (TSHA), Gyre Therapeutics (GYRE), ArriVent BioPharma (AVBP), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors Phathom Pharmaceuticals Anavex Life Sciences Akebia Therapeutics Valneva Niagen Bioscience Sana Biotechnology Taysha Gene Therapies Gyre Therapeutics ArriVent BioPharma BGM Group Heron Therapeutics (NASDAQ:HRTX) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation. Which has stronger earnings and valuation, HRTX or PHAT? Heron Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Heron Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeron Therapeutics$144.29M1.43-$13.58M-$0.02-67.50Phathom Pharmaceuticals$55.25M15.64-$334.33M-$4.73-2.58 Does the media prefer HRTX or PHAT? In the previous week, Heron Therapeutics had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 3 mentions for Heron Therapeutics and 2 mentions for Phathom Pharmaceuticals. Heron Therapeutics' average media sentiment score of 1.11 beat Phathom Pharmaceuticals' score of 0.93 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in HRTX or PHAT? 80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 5.9% of Heron Therapeutics shares are owned by company insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate HRTX or PHAT? Heron Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 233.33%. Phathom Pharmaceuticals has a consensus target price of $17.50, indicating a potential upside of 43.68%. Given Heron Therapeutics' higher possible upside, research analysts plainly believe Heron Therapeutics is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, HRTX or PHAT? Heron Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Is HRTX or PHAT more profitable? Heron Therapeutics has a net margin of -0.62% compared to Phathom Pharmaceuticals' net margin of -289.51%. Company Net Margins Return on Equity Return on Assets Heron Therapeutics-0.62% N/A -0.40% Phathom Pharmaceuticals -289.51%N/A -90.40% SummaryHeron Therapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$206.94M$2.80B$5.75B$9.76BDividend YieldN/A1.68%4.10%4.04%P/E Ratio-67.5022.8083.2726.59Price / Sales1.43735.21535.03111.31Price / CashN/A174.6137.4459.26Price / Book-7.505.9810.556.58Net Income-$13.58M$32.94M$3.27B$265.95M7 Day Performance-3.57%-1.28%0.40%0.17%1 Month Performance-21.97%5.64%7.31%3.90%1 Year Performance-30.05%-3.15%46.58%19.67% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.0003 of 5 stars$1.35-2.9%$4.50+233.3%-30.1%$206.94M$144.29M-67.50300Positive NewsPHATPhathom Pharmaceuticals2.5576 of 5 stars$11.57-2.9%$17.50+51.3%-26.3%$820.78M$55.25M-2.45110AVXLAnavex Life Sciences3.8135 of 5 stars$9.40-1.4%$44.00+368.1%+60.1%$807.40MN/A-16.4940News CoveragePositive NewsAnalyst ForecastAKBAAkebia Therapeutics3.7508 of 5 stars$3.03-5.0%$6.75+122.8%+102.6%$803.39M$203.73M-17.82430VALNValneva1.9776 of 5 stars$9.43-19.0%$16.00+69.7%+20.2%$802.40M$183.52M-9.62700High Trading VolumeNAGENiagen Bioscience2.0084 of 5 stars$10.03+0.5%$13.42+33.8%+187.0%$799.92M$116.30M47.76120SANASana Biotechnology2.854 of 5 stars$3.35-6.4%$8.00+138.8%-49.4%$796.66MN/A-3.16380TSHATaysha Gene Therapies2.8243 of 5 stars$2.92-2.7%$8.29+183.8%+30.4%$796.58M$8.33M-8.59180Positive NewsGYREGyre Therapeutics1.2956 of 5 stars$8.20+0.2%N/A-43.8%$789.77M$102.19M820.8240News CoverageAnalyst ForecastAnalyst RevisionAVBPArriVent BioPharma2.3689 of 5 stars$19.35-3.8%$39.14+102.3%-28.5%$785.03MN/A-4.8140News CoveragePositive NewsAnalyst RevisionBGMBGM GroupN/A$8.03+0.1%N/A+7.7%$780.68M$25.10M0.00298 Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Anavex Life Sciences Competitors Akebia Therapeutics Competitors Valneva Competitors Niagen Bioscience Competitors Sana Biotechnology Competitors Taysha Gene Therapies Competitors Gyre Therapeutics Competitors ArriVent BioPharma Competitors BGM Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRTX Stock Alerts